Active substance
Sunitinib malate
- US FDA 10
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| SUTENT | EQ 12.5MG BASE; EQ 25MG BASE; EQ 50MG BASE; EQ 37.5MG BASE | capsule · oral | CPPI CV | Prescription | 26 Jan 2006 |
| SUTENT | EQ 12.5MG BASE; EQ 25MG BASE; EQ 50MG BASE | capsule · oral | CPPI CV | Prescription | 26 Jan 2006 |
| SUNITINIB MALATE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE | capsule · oral | SUN PHARM | Prescription | 16 Aug 2021 |
| SUNITINIB MALATE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE | capsule · oral | TEVA PHARMS USA | Prescription | 30 Nov 2021 |
| SUNITINIB MALATE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE | capsule · oral | MYLAN | Prescription | 6 Dec 2021 |
| SUNITINIB MALATE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE | capsule · oral | DR REDDYS | Prescription | 11 Apr 2022 |
| SUNITINIB MALATE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE | capsule · oral | FOSUN WANBANG | Prescription | 21 Aug 2023 |
| SUNITINIB MALATE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE | capsule · oral | NATCO PHARMA | Prescription | 24 Oct 2023 |
| SUNITINIB MALATE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE | capsule · oral | EUGIA PHARMA | Prescription | 14 Mar 2024 |
| SUNITINIB MALATE | EQ 12.5MG BASE; EQ 25MG BASE; EQ 37.5MG BASE; EQ 50MG BASE | capsule · oral | MSN | Prescription | 14 Feb 2025 |
Safety signals and safety-related labeling changes
- US FDA 30 Aug 2021 SUTENT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.